Filtered By:
Specialty: Neurology
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 360 results found since Jan 2013.

Atorvastatin Treatment Is Associated with Increased BDNF Level and Improved Functional Recovery after Atherothrombotic Stroke (S31.007)
Conclusions: Our results demonstrated that atorvastatin treatment was associated with increased BDNF level and improved functional recovery after atherothrombotic stroke. This study indicates that atorvastatin-related elevation in BDNF may promote functional recovery in stroke patients.Disclosure: Dr. Zhang has nothing to disclose. Dr. Mu has nothing to disclose. Dr. Gao has nothing to disclose. Dr. Huang has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Zhang, J., Mu, X., Gao, Z., Huang, Y. Tags: Stroke Risk, Outcomes, and Complications Source Type: research

HMG-CoA Reductase Inhibitor (Statin) Prescribing for Ischemic Stroke Patients at Hospital Discharge (P2.306)
Conclusions: Our observations suggest that neurologists may be more likely to prescribe a statin at the time of discharge for whites in group 3 (diabetics age 40-75 with LDL 70-189 without ASCVD) when compared to their black counterparts. Further research is needed to determine if racial disparities exist in discharge statin prescribing for stroke survivors.Disclosure: Dr. Albright has nothing to disclose. Dr. Vahidy has nothing to disclose. Dr. Sisson has nothing to disclose. Dr. Samai has nothing to disclose. Dr. Schluter has nothing to disclose. Dr. Martin-Schild has received personal compensation for activities with Genentech.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Vahidy, F., Moore, M., Samai, A., Schluter, L., Martin-Schild, S. Tags: Stroke Systems of Care Source Type: research

COLADAS: Caribbean Origin Latin Americans Disparities in Acute Stroke (S4.002)
Conclusions: Our study reveals intrinsic sex differences that may imply under treatment. Understanding the reasons underlying these "sex-gaps" is critical. Study Supported By: Award Number Grants 5S21MD000242 and 5S21MD000138, from the National Center for Minority Health and Health Disparities, National Institutes of Health (NCMHD-NIH).Disclosure: Dr. Teron Molina has nothing to disclose. Dr. Rodríguez Centeno has nothing to disclose. Dr. Santiago has nothing to disclose. Dr. López Valentín has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Teron Molina, I., Rodriguez Centeno, A., Santiago, F., Lopez Valentin, M. Tags: Health Disparities and Sex Differences in Stroke Source Type: research

African Americans Are Less Likely to Be Adherent to Statins After Ischemic Stroke: An Analysis of Medicare Beneficiaries Following Hospital Discharge (S4.003)
Conclusions: African Americans may not be obtaining the recurrent stroke prevention therapy provided by statins, possibly contributing to the higher rate of recurrent stroke in this population.Disclosure: Dr. Albright has nothing to disclose. Dr. Blackburn has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Beasley has nothing to disclose. Dr. Limdi has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Muntner has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Blackburn, J., Zhao, H., Beasley, T., Limdi, N., Howard, V., Muntner, P. Tags: Health Disparities and Sex Differences in Stroke Source Type: research

Quality of Care for Patients with TIA with an Eye towards Quality Improvement: How Are We Doing? (P6.036)
Conclusion: Overall, care provided was guideline-concordant, but some patients with TIA are receiving suboptimal care, even among those admitted to a Stroke Center who are routinely admitted or seen by neurology. There are opportunities for improvement in TIA care, especially in statin treatment of eligible TIA patients.Disclosure: Dr. Kalaria has nothing to disclose. Dr. Flair has nothing to disclose. Dr. Cronin has nothing to disclose. Dr. Kittner has nothing to disclose. Dr. Phipps has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kalaria, C., Flair, Z., Cronin, C., Kittner, S., Phipps, M. Tags: Telestroke and Other Innovations and TIA Source Type: research

Recanalization Therapy of Acute Internal Carotid Artery Occlusion: Comparison of Carotid Endarterectomy and Endovascular Treatment (P6.068)
CONCLUSIONS: Data from this national multicenter registry showed that both CEA and EVT (including bridging therapy) represent safe and effective recanalization methods of acute ICAo. Better clinical outcome was observed in patients without intracranial occlusion and with achieved recanalization. Study Supported by: Internal Grant Agency of Ministry of Health of the Czech Republic grants NT/11046-6/2010, NT/13498-4/2012.Disclosure: Dr. Herzig has nothing to disclose. Dr. Roubec has nothing to disclose. Dr. Skoloudik has nothing to disclose. Dr. Kuliha has nothing to disclose. Dr. Sanak received personal compensation for act...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Herzig, R., Roubec, M., Skoloudik, D., Kuliha, M., Sanak, D., Waishaupt, J., Vitkova, E., Blejcharova, K., Krajickova, D., Tomek, A., Krajina, A., Prochazka, V., Kocher, M., Charvat, F., Fadrna, T., Zapletalova, J., Valis, M. Tags: Cerebrovascular Disease: Miscellaneous Interventions Source Type: research

Hepatic S1P Deficiency Reduces Atheroma Formation in LDLR-/- Mice (P5.227)
Conclusion: Hepatic S1P is a physiological modulator of plasma lipid metabolism through its regulation of VLDL secretion, especially when LDLR function is compromised. Utilizing genetic models, our data demonstrate the protective effect of hepatic S1P inhibition for reducing atheroma formation. Thus, S1P inhibitors could be potentially used to treat atherosclerosis and prevent stroke.Disclosure: Dr. Jin has nothing to disclose. Dr. Basu has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Jin, W., Basu, D. Tags: Cerebrovascular Disease: Animal Models and In Vitro Models Source Type: research

COLADAS: Caribbean Origin Latin Americans Disparities in Acute Stroke (I5.006)
Conclusions: Our study reveals intrinsic sex differences that may imply under treatment. Understanding the reasons underlying these "sex-gaps" is critical. Study Supported By: Award Number Grants 5S21MD000242 and 5S21MD000138, from the National Center for Minority Health and Health Disparities, National Institutes of Health (NCMHD-NIH).Disclosure: Dr. Teron Molina has nothing to disclose. Dr. Rodríguez Centeno has nothing to disclose. Dr. Santiago has nothing to disclose. Dr. López Valentín has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Teron Molina, I., Rodriguez Centeno, A., Santiago, F., Lopez Valentin, M. Tags: Sex-related Factors in Neurological Disease Data Blitz Presentations Source Type: research

White Matter Hyperintensity in Patients with Mild Traumatic Brain Injury Correlates with Higher Coated-Platelet Levels (P3.323)
Conclusions: These preliminary results suggest that increased platelet procoagulant potential and age are significant predictors for the presence of WMH in mTBI, many years after the injury. Additional studies aimed at determining the long-term impact of these findings is warranted.Disclosure: Dr. Prodan has received research support from the Veterans Affairs Office. Dr. Vincent has nothing to disclose. Dr. Guthery has nothing to disclose. Dr. Mathews has nothing to disclose. Dr. Sadler has nothing to disclose. Dr. Dale has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Prodan, C., Vincent, A., Guthery, L., Mathews, E., Sadler, D., Dale, G. Tags: Neuro Trauma and Sports Neurology Source Type: research

African Americans Are Less Likely to Be Adherent to Statins After Ischemic Stroke: An Analysis of Medicare Beneficiaries Following Hospital Discharge (I2.006)
Conclusions: African Americans may not be obtaining the recurrent stroke prevention therapy provided by statins, possibly contributing to the higher rate of recurrent stroke in this population.Disclosure: Dr. Albright has nothing to disclose. Dr. Blackburn has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Beasley has nothing to disclose. Dr. Limdi has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Muntner has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Blackburn, J., Zhao, H., Beasley, T., Limdi, N., Howard, V., Muntner, P. Tags: Stroke in the Elderly and Young: Challenges for the Next Decade Data Blitz Presentations Source Type: research

Why Delay the Control of Modifiable Vascular Risk Factors (MVRF) Until the Occurrence of an Ischemic Stroke (iStroke)? (P1.180)
Conclusions: We found that the management of MVRF increases after the first ischemic event and this improves the early prognosis of iStroke (Rankin-based disability). It is important to improve the management of these factors in the setting of primary prevention.Disclosure: Dr. Pagano Ajolfi has nothing to disclose. Dr. Sanz has nothing to disclose. Dr. Alfonso has nothing to disclose. Dr. Seijas has nothing to disclose. Dr. Arrébola has nothing to disclose. Dr. Giannaula has received personal compensation for activities with Boehringer Ingelheim.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Pagano Ajolfi, S., Sanz, P., Alfonso, A., Seijas, M., Arrebola, M., Giannaula, R. Tags: Cerebrovascular Disease: Risk Factors and Prevention Source Type: research

Statin use after intracerebral hemorrhage: a 10‐year nationwide cohort study
ConclusionHydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on recurrent ICH or other components of the composite outcome. Additional studies are required to clarify the biological mechanisms underlying these observations. Statin therapy has demonstrated benefits in ischemic stroke patients, but statin use and intracerebral hemorrhage (ICH) remain a concern. Hydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on rec...
Source: Brain and Behavior - March 31, 2016 Category: Neurology Authors: Shu‐Yu Tai, Feng‐Cheng Lin, Chung‐Yin Lee, Chai‐Jan Chang, Ming‐Tsang Wu, Chen‐Yu Chien Tags: Original Research Source Type: research

Statin therapy in acute ischemic stroke: Time for large randomized trials?
Despite improvements in stroke mortality coupled with therapeutic advances, stroke patients often face the prospect of substantial disability. Novel strategies are clearly needed to further improve stroke outcomes. These might include new indications for previously licensed drugs proven effective and safe in related disease processes,1 such as statins. Unlike strong evidence supporting statin use in cardiovascular risk reduction and acute myocardial ischemia, their effects on cerebral tissue and potential benefits on stroke outcomes remain poorly understood and understudied. The only current stroke-specific indication for ...
Source: Neurology - March 21, 2016 Category: Neurology Authors: Charidimou, A., Merwick, A. Tags: All Cerebrovascular disease/Stroke, Infarction EDITORIALS Source Type: research

Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke
Conclusion: Statin pretreatment in patients with acute LAA appears to be associated with better early outcomes regarding neurologic improvement, disability, survival, and stroke recurrence.
Source: Neurology - March 21, 2016 Category: Neurology Authors: Tsivgoulis, G., Katsanos, A. H., Sharma, V. K., Krogias, C., Mikulik, R., Vadikolias, K., Mijajlovic, M., Safouris, A., Zompola, C., Faissner, S., Weiss, V., Giannopoulos, S., Vasdekis, S., Boviatsis, E., Alexandrov, A. W., Voumvourakis, K., Alexandrov, A Tags: All Cerebrovascular disease/Stroke, Infarction ARTICLE Source Type: research

10-Second heart rate variability and cognitive function in old age
Conclusions: Participants with lower 10-second HRV have worse performance in reaction time and processing speed and experience steeper decline in their processing speed, independent of medications, cardiovascular risk factors, and comorbidities.
Source: Neurology - March 21, 2016 Category: Neurology Authors: Mahinrad, S., Jukema, J. W., van Heemst, D., Macfarlane, P. W., Clark, E. N., de Craen, A. J. M., Sabayan, B. Tags: All Cerebrovascular disease/Stroke, All Cognitive Disorders/Dementia, All epidemiology ARTICLE Source Type: research